Based on the companies progression in this new drug class, I have a gut feeling we are testing the drug against hypertensive agents like sartans. Knowing we are far superior than FDA approved first line treatments in myocardial reperfusion, there is a 50 billion dollar high blood pressure market that is looking for a new drug class to disrupt and based off previous mice studies TRPC3 channel antagonist lowers blood pressure. NYR is a TRPC3,6,7 inhibitor. Watch out for another indication to come into play as time goes on
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
29.5¢ |
Change
-0.003(0.84%) |
Mkt cap ! $70.10M | |||
| Open | High | Low | Value | Volume |
| 29.5¢ | 29.5¢ | 28.0¢ | $156.4K | 537.2K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 2500 | 29.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 30.0¢ | 259493 | 4 |
View Market Depth
| Last trade - 15.24pm 12/08/2025 (20 minute delay) ? |
| NYR (ASX) Chart |